Please assess the completion status of the following clinical trial:

Trial Title: Drug-eluting Balloon Versus Drug-eluting Stent for High Bleeding Risk Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years old or older with an ischemic de-novo lesion(s) in a 2.5 - 4.0 mm reference diameter coronary artery suitable for elective percutaneous coronary intervention, in context of acute coronary syndrome or chronic coronary syndrome with evidence of ischemia by non-invasive study or pressure guidewire that can be treated by DEB or DES, and has at least 1 major or 2 minor Academic Research Consortium High Bleeding Risk criteria:~* Major criteria:~  1. Anticipated use of long-term oral anticoagulation~ 2. Severe or end-stage CKD (eGFR \<30 mL/min)~ 3. Hemoglobin \< 11 g/dL~ 4. Spontaneous bleeding requiring hospitalization or transfusion in the last 6 months, or any time, if recurrent.~ 5. Moderate or severe baseline thrombocytopenia (\<100,000/uL)~ 6. Chronic bleeding diathesis~ 7. Liver cirrhosis with portal hypertension~ 8. Active malignancy (excluding nonmelanoma skin cancer) within the past 12 months~ 9. Previous spontaneous intracranial hemorrhage~ 10. Previous traumatic intracranial hemorrhage within the past 12 months~ 11. Presence of Brain arteriovenous malformation (AVM)~ 12. Moderate or severe ischemic stroke (NIHSS score equal or more than 5) within the past 6 months~ 13. Non deferrable major surgery while on DAPT~ 14. Recent major surgery or major trauma within 30 days before PCI~* Minor Criteria:~  1. Age 75 years old and older~ 2. Moderate Chronic Kidney Disease (CKD) (eGFR 30-59 mL/min)~ 3. Hemoglobin 11 - 12.9 g/dL in men and 11 - 11.9 g/dL in women~ 4. Spontaneous bleeding requiring hospitalization or transfusion within the past 12 months, not meeting major criterion~ 5. Long term use of NSAIDs or steroids~ 6. Any ischemic stroke at any time not meeting major criterion~Exclusion Criteria:~* STEMI undergoing primary PCI~* Any ACS undergoing urgent PCI~* Cardiogenic shock or resuscitation with uncertain neurological status at arrival to PCI~* Unprotected left main lesion~* Life expectancy \< 12 months~* Reference vessel diameter \< 2.5 mm or \> 4.0 mm~* Bifurcation lesion requiring 2-stent technique~* Chronic total occlusion~* In-stent restenosis~* Dissection affecting the flow (TIMI\<3) or significant recoil (\>30% in main branch, \>50% in side branch) after predilatation~* Inability to give written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Eluting Balloon (DEB) (Type: EXPERIMENTAL): High Bleeding Risk patients treated with 2.5 - 4.0 mm drug-eluting balloons (DEB). Bailout stenting is permitted in case of a flow-limiting dissection or significant recoil (\>30% in main branch and \>50% side-branch), includes both stable coronary artery disease (SCAD) and acute coronary syndromes (ACS) patients undergoing elective Percutaneous Coronary Intervention (PCI).
- Drug Eluting Stents (DES) (Type: ACTIVE_COMPARATOR): High Bleeding Risk patients treated with 2.5 - 4.0 mm drug-eluting stents (DES). Includes both stable CAD and ACS patients undergoing elective PCI.

Based on this trial design, predict the completion outcome and termination type (if applicable).